To evaluate the effect of transarterial hyperthemic perfusion chemotherapy combined with arterial superselective embolization for the treatment of unresectable colorectal cancer liver metastasis.

A retrospective analysis of the clinical data of 39 cases with colorectal cancer liver metastasis was conducted. The treatment group included 22 cases. Transarterial hyperthemic perfusion (51 ℃, 1 h) was performed in superior mesenteric artery and hepatic artery respectively. And then super selective artery embolization was performed in the feeding artery of hepatic lesions. Control group included 17 cases who received traditional transcatheter arterial chemoembolization (TACE) . The short-term effect was evaluated by objective response rate and clinical benefit rate. One year survival rate was used to evaluate the long-term effect. At the same time, adverse reactions of two groups were recorded.

There was no significant difference between the basic clinical characteristics of patients in two groups. The objective effective rate showed no significant difference (27.3% vs. 23.5%, P>0.05) between the two groups and the clinical benefit rate also showed no significant difference (81.8% vs. 76.5%, P>0.05) . However, the one year survival rate of study group was significantly higher than the control group (63.2% vs. 46.7%, P< 0.05) . There were no artery vasospasm, occlusion, or any other serious adverse reactions in two groups.

The long-term effect of transarterial hyperthemic perfusion chemotherapy combined with arterial superselective embolization on unresectable colorectal cancer liver metastasis is superior to that of conventional TACE.